Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.44 |
| ▸ | METAP2 | P50579 | 3/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2430327 | 0.80 | TRPA1 (0.42) | TRPA1METAP2AXLMETNOS1 | |
| SCHEMBL5407599 | 0.79 | MET (0.44) | TRPA1METAP2AXLMETNOS1 | |
| SCHEMBL13745163 | 0.79 | NOS1 (0.46) | TRPA1METAP2AXLMETNOS1 | |
| SCHEMBL2427200 | 0.78 | AXL (0.46) | TRPA1METAP2AXLMET | |
| SCHEMBL15808424 | 0.75 | METAP2 (0.39) | TRPA1METAP2AXLMETNOS1 | |
| SCHEMBL31411470 | 0.75 | TRPA1 (0.50) | TRPA1METAP2AXLNOS1IDO1 | |
| SCHEMBL27051452 | 0.75 | MET (0.39) | TRPA1METAP2AXLMETNOS1 | |
| SCHEMBL4141136 | 0.75 | BRD4 (0.43) | TRPA1METAP2AXLMETNOS1 | |
| SCHEMBL457549 | 0.74 | NOS1 (0.53) | TRPA1METAP2AXLMETNOS1 | |
| SCHEMBL30751781 | 0.74 | NOS1 (0.53) | TRPA1METAP2AXLMETNOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024175086-A1 | ARYL TRICYCLIC STING AGONIST AND USE THEREOF | 深圳真实生物医药科技有限公司 | 2024-08-29 | — | — | WO | disclosed |
| WO-2023109461-A1 | BENZOTHIOPHENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 中国科学院上海药物研究所 | 2023-06-22 | — | — | WO | disclosed |
| CN-101558040-B | Dihydropyridine derivatives useful as protein kinase inhibitors | BAYER SCHERING PHARMA AG | 2013-03-27 | — | — | CN | disclosed |
| EP-2121608-B1 | DIHYDROPYRIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | BAYER IP GMBH (DE) | 2012-11-14 | — | — | EP | disclosed |
| US-8198456-B2 | e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-8198456-B2 | e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-8198456-B2 | e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| WO-2010020307-A2 | INDAZOLE-5-CARBOXYLIC ACID HYDRAZIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020307-A2 | INDAZOLE-5-CARBOXYLIC ACID HYDRAZIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
| CN-1300116-C | 1H-indazole compounds | EISAI CO LTD (JP) | 2007-02-14 | — | — | CN | disclosed |
| US-6982274-B2 | 1H-indazole compound | EISAI CO., LTD. (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| CN-1656079-A | Pyrazole compounds and pharmaceutical compositions containing the same | EISAI CO LTD (JP) | 2005-08-17 | — | — | CN | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
| CN-1512987-A | Novel 1H-indazole compound | ������������ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| US-20040127538-A1 | Novel 1h-indazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1380576-A1 | NOVEL 1H-INDAZOLE COMPOUND | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | TRPA1 1859/4885METAP2 4792/4885AXL 1396/4885 |
| US-20040127538-A1 | Novel 1h-indazole compound | MAPK1, MAPK14, MAPK3 | TRPA1 755/4885METAP2 4837/4885AXL 2312/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | TRPA1 308/4885METAP2 4773/4885AXL 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.